Table 3 List of the eye-related pathologies experienced by the 14 patients from the safety population not reaching monocular CDVA equal or better than 0.3 logMAR
Case number | CDVA (logMAR) | Factors contributing to CDVA > 0.3 logMAR | |
|---|---|---|---|
Preop. | 12 months | ||
1 | 0.4 | 0.6 | Diabetic macular oedema; diabetic proliferative retinopathy; clinically significant PCO requiring Nd:YAG |
2 | 1.0 | 0.92 | Amblyopia |
3 | 0.4 | 0.4 | No distinct ocular disorders despite diabetes; clinically significant PCO requiring Nd:YAG |
4 | 2.3 | 0.7 | Cornea guttata; macular atrophy; early stage band keratopathy |
5 | 1.3 | 1.3 | Retinal scar (geographic atrophy); amblyopia |
6 | 0.4 | 0.5 | Dry macular degeneration; geographic atrophy |
7 | 0.6 | 0.6 | Amblyopia; macular traction; retinoschisis |
8 | 0.4 | 0.5 | Dry macular degeneration; adult vitelliform maculopathy |
9 | 0.4 | 1.0 | Cornea guttata; ocular hypertension requesting surgical intervention (trabeculectomy) and leading to hyperaemia and hyphema |
10 | 0.4 | 0.4 | Glaucoma; dry macular degeneration; drusen macula; glaucomatous papilla; amblyopia |
11 | 0.52 | 0.34 | Epiretinal membrane |
12 | 0.3 | 0.4 | No distinct ocular disorders despite diabetes mellitus; clinically significant PCO requiring Nd:YAG |
13 | 0.6 | 0.32 | Age-related macular degeneration; transition from drusen age-related macular degeneration to neovascular wet age-related macular degeneration; corneal erosion; clinically significant PCO |
14 | 0.7 | 0.38 | Slight age-related macular degeneration with drusen; vitreous detachment; clinically significant PCO requiring Nd:YAG |